GlassScriptPhysician profile
Sandra R Stites
NPI 1295731875
$1,106.43
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $37.51 · 2021: $233 · 2022: $214 · 2024: $67.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $67.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $67.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $310.71 | 2019-2024 | |
| Abbvie INC. | $212.63 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $109.89 | 2019 | |
| Coopersurgical, INC. | $102.07 | 2019-2022 | |
| Intuitive Surgical, INC. | $76.39 | 2019 | |
| Myovant Sciences INC. | $65.33 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.46 | 2019-2021 | |
| Exeltis, USA INC. | $36.58 | 2019-2021 | |
| Hologic Sales and Service, LLC | $35.77 | 2019-2024 | Thinprep 2000 Processor, Aptima |
| Agile Therapeutics, INC. | $20.40 | 2021 | |
| Viiv Healthcare Company | $19.20 | 2024 | Apretude |
| Therapeuticsmd, INC. | $18.13 | 2022 | |
| Organon LLC | $17.01 | 2021 | |
| Minerva Surgical, INC | $14.50 | 2019 | |
| Glaxosmithkline, LLC. | $13.36 | 2024 | Rotarix, Pediarix, Bexsero |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Stites listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.